Results 191 to 200 of about 2,872,365 (306)

Opioid use disorder in custodial settings: Continuity of opioid agonist therapy at a critical clinical inflection point. [PDF]

Can Fam Physician
Albert OM, Arthur A, Beshara F.
europepmc   +1 more source

In silico prediction of novel effective combinational treatment of chronic pain in individual patients: A joint white paper of the H2020 QSPainRelief consortium

British Journal of Pharmacology, EarlyView.
Abstract Opioids are prescribed widely for chronic pain despite well‐recognised risks and variable long‐term benefit, reflecting the lack of effective alternatives for many patients. Combination therapies offer a promising strategy to enhance efficacy whilst reducing side effects.
André Mouraux, Solenn Gousset, Beltrán Alvarez, Monica Baiula, Wouter Bakker, Andrea Bedini, Monir Bertayli, Divakar Budda, Robert Carr, Elisabetta Cuna, Óscar Díaz, Nina Donner, Jesús Giraldo, Geert‐Jan Groeneveld, Berfin Gülave, David Guydan, Hemme Hijma, Rafael Maldonado, Pedro Renault, Carlos Rinaudo, Jeroen Elaissaiss‐Schaap, Athan Spiros, Sara Stoeber, Petri Takkala, Daan van Valkengoed, Coen van Hasselt, Elizabeth (Liesbeth) C.M. de Lange   +26 more
wiley   +1 more source

Gut microbiota as a novel therapeutic target for eating disorders and obesity

British Journal of Pharmacology, EarlyView.
The graphical abstract highlights the bidirectional interaction between the gut microbiota and central homeostatic and hedonic mechanisms regulating food intake, which contributes to overweight and obesity. It also illustrates emerging microbiota‐based biomarkers and therapeutic strategies (including prebiotics, probiotics, postbiotics, synbiotics and ...
Solveiga Samulėnaitė, Victor Mathis, Emmanuel Darcq, Aurelijus Burokas, Elena Martín‐García, Rafael Maldonado   +5 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

The pathway to establishing and implementing opioid agonist therapy (OAT) for people who inject drugs in Nairobi, Kenya. [PDF]

Front Public Health
Koech E, Welsh C, Karanja M, Boit J, Wangusi R, Awuor P, Munyao O, Masai T, Wafula S, Ngunu C, Kenyatta O, Mutisya I, Mwangi J, Gichuhi B, Lyn A, Stafford K, Lascko T, Ndichu G, Ng'eno C.   +18 more
europepmc   +1 more source

Systematic profiling reveals broad G protein coupling and context‐dependent modulation of cyclic AMP by the orphan receptor GPR139

British Journal of Pharmacology, EarlyView.
Background and Purpose G protein‐coupled receptors (GPCRs) are major drug targets, yet many orphan receptors remain poorly characterized. GPR139 has been implicated in CNS disorders, including schizophrenia and depression, but its signalling mechanisms remain unclear.
Boris Trapkov, Hans Bräuner, Alexander Sebastian Hauser   +2 more
wiley   +1 more source

Signal detection and characterisation of a novel drug–drug interaction between methadone and a synthetic cannabinoid receptor agonist

British Journal of Pharmacology, EarlyView.
Background and Purpose Little is known about how synthetic cannabinoid receptor agonist (SCRA) co‐use with other psychoactive substances may exacerbate risk of death. This study aimed to characterise the polypharmacy of deaths where SCRAs were detected at post‐mortem, investigate the cardiotoxicity of SCRAs and probe their inhibition of human ether‐a ...
Kirsten L. Rock, Louise M. Hesketh, Hongwei Cheng, Shuoqi Chen, Simon Hudson, Graeme Henderson, Jules C. Hancox, Michael J. Shattock, Michael J. Curtis, Caroline S. Copeland   +9 more
wiley   +1 more source

A methodological framework for constructing opioid agonist therapy episodes in administrative health data. [PDF]

BMC Methods
Yazdani K, Tam C, Fisher CC, Emerson SD, Trigg J, Kooij KW, De Vera MA, Vila-Rodriguez F, Hogg RS, Montaner JSG, Lima VD.   +10 more
europepmc   +1 more source

Natural product‐derived TRPM7 channel inhibitors in neurological injury: Mechanisms, pharmacological potential and translational challenges

British Journal of Pharmacology, EarlyView.
Disruption of intracellular ionic homeostasis is a convergent pathological feature across diverse neurological injuries and disorders, including ischaemic and haemorrhagic stroke, hypoxic–ischaemic brain injury, traumatic brain injury, epilepsy and brain tumour.
Xinyang Zhang, Hio Lam Ho, F. David Horgen, Andrea Fleig, Zhong‐Ping Feng, Hong‐Shuo Sun   +5 more
wiley   +1 more source

Opioid agonist therapy.

Canadian family physician Medecin de famille canadien, 2017
Kathleen, Broad, Hector Ahmed, Colon-Rivera, Lamia, Haque   +2 more
openaire   +1 more source